HRP20110005T1 - Spoj tricikličkog benzopirana kao anti-aritmijskog sredstva - Google Patents
Spoj tricikličkog benzopirana kao anti-aritmijskog sredstva Download PDFInfo
- Publication number
- HRP20110005T1 HRP20110005T1 HR20110005T HRP20110005T HRP20110005T1 HR P20110005 T1 HRP20110005 T1 HR P20110005T1 HR 20110005 T HR20110005 T HR 20110005T HR P20110005 T HRP20110005 T HR P20110005T HR P20110005 T1 HRP20110005 T1 HR P20110005T1
- Authority
- HR
- Croatia
- Prior art keywords
- group
- amino
- pyrano
- dihydro
- quinolin
- Prior art date
Links
- -1 benzopyran compound Chemical class 0.000 title claims 2
- 239000003416 antiarrhythmic agent Substances 0.000 title abstract 2
- 150000001562 benzopyrans Chemical class 0.000 claims abstract 20
- 150000003839 salts Chemical class 0.000 claims abstract 19
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract 16
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims abstract 8
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims abstract 7
- 125000003277 amino group Chemical group 0.000 claims abstract 6
- 229910052717 sulfur Inorganic materials 0.000 claims abstract 3
- 125000006553 (C3-C8) cycloalkenyl group Chemical group 0.000 claims abstract 2
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims abstract 2
- 229910052760 oxygen Inorganic materials 0.000 claims abstract 2
- 125000005843 halogen group Chemical group 0.000 claims 9
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 3
- CHIOVPNYOWEUJW-UHFFFAOYSA-N 2,2,7-trimethyl-4-(2-phenylethylamino)-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound C12=CC3=NC(C)=CC=C3C=C2OC(C)(C)C(O)C1NCCC1=CC=CC=C1 CHIOVPNYOWEUJW-UHFFFAOYSA-N 0.000 claims 2
- ZZUSANGEAUESFL-UHFFFAOYSA-N 7-(hydroxymethyl)-2,2,9-trimethyl-4-(2-phenylethylamino)-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound OC1C(C)(C)OC=2C=C3C(C)=CC(CO)=NC3=CC=2C1NCCC1=CC=CC=C1 ZZUSANGEAUESFL-UHFFFAOYSA-N 0.000 claims 2
- NGWVFMQMEXBFMD-UHFFFAOYSA-N 7-chloro-2,2,9-trimethyl-4-(2-phenylethylamino)-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound OC1C(C)(C)OC=2C=C3C(C)=CC(Cl)=NC3=CC=2C1NCCC1=CC=CC=C1 NGWVFMQMEXBFMD-UHFFFAOYSA-N 0.000 claims 2
- UVSBPVGBBJBIPA-UHFFFAOYSA-N 7-chloro-2,2,9-trimethyl-4-(2-pyridin-3-ylethylamino)-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound OC1C(C)(C)OC=2C=C3C(C)=CC(Cl)=NC3=CC=2C1NCCC1=CC=CN=C1 UVSBPVGBBJBIPA-UHFFFAOYSA-N 0.000 claims 2
- KCHOBYCFOXAKNM-UHFFFAOYSA-N 7-chloro-4-(2-cyclohexylethylamino)-2,2,9-trimethyl-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound OC1C(C)(C)OC=2C=C3C(C)=CC(Cl)=NC3=CC=2C1NCCC1CCCCC1 KCHOBYCFOXAKNM-UHFFFAOYSA-N 0.000 claims 2
- HZUJFGLZSGYMQT-UHFFFAOYSA-N 8-hydroxy-7,7-dimethyl-9-(2-phenylethylamino)-8,9-dihydro-1h-pyrano[3,2-g][1,4]benzoxazin-2-one Chemical compound OC1C(C)(C)OC2=CC=3OCC(=O)NC=3C=C2C1NCCC1=CC=CC=C1 HZUJFGLZSGYMQT-UHFFFAOYSA-N 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- LMVGPQNBHMECBB-UHFFFAOYSA-N 2,2,7,9-tetramethyl-4-(2-phenylethylamino)-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound C12=CC3=NC(C)=CC(C)=C3C=C2OC(C)(C)C(O)C1NCCC1=CC=CC=C1 LMVGPQNBHMECBB-UHFFFAOYSA-N 0.000 claims 1
- IDLTUNKJYAGSFN-UHFFFAOYSA-N 2,2-dimethyl-4-(2-phenylethylamino)-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound OC1C(C)(C)OC2=CC3=CC=CN=C3C=C2C1NCCC1=CC=CC=C1 IDLTUNKJYAGSFN-UHFFFAOYSA-N 0.000 claims 1
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims 1
- XEQQREZFQJPKEY-UHFFFAOYSA-N 3,3-dimethyl-1-(2-phenylethylamino)-1,2-dihydropyrano[3,2-f]quinolin-2-ol Chemical compound OC1C(C)(C)OC2=CC=C3N=CC=CC3=C2C1NCCC1=CC=CC=C1 XEQQREZFQJPKEY-UHFFFAOYSA-N 0.000 claims 1
- OWYYYCYHGORREH-UHFFFAOYSA-N 3-hydroxy-2,2,9-trimethyl-4-(2-phenylethylamino)-3,4-dihydropyrano[2,3-g]quinoline-7-carbonitrile Chemical compound OC1C(C)(C)OC=2C=C3C(C)=CC(C#N)=NC3=CC=2C1NCCC1=CC=CC=C1 OWYYYCYHGORREH-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- 125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 claims 1
- ACZVHCBJCSMHIL-UHFFFAOYSA-N 7-chloro-2,2,9-trimethyl-4-(pentylamino)-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound C1=C(Cl)N=C2C=C3C(NCCCCC)C(O)C(C)(C)OC3=CC2=C1C ACZVHCBJCSMHIL-UHFFFAOYSA-N 0.000 claims 1
- ODTMNOQRTBPFTK-UHFFFAOYSA-N 7-chloro-4-[2-(4-chlorophenyl)ethylamino]-2,2,9-trimethyl-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound OC1C(C)(C)OC=2C=C3C(C)=CC(Cl)=NC3=CC=2C1NCCC1=CC=C(Cl)C=C1 ODTMNOQRTBPFTK-UHFFFAOYSA-N 0.000 claims 1
- SJROYWSEXZWKAM-UHFFFAOYSA-N 7-chloro-4-[2-(4-fluorophenyl)ethylamino]-2,2,9-trimethyl-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound OC1C(C)(C)OC=2C=C3C(C)=CC(Cl)=NC3=CC=2C1NCCC1=CC=C(F)C=C1 SJROYWSEXZWKAM-UHFFFAOYSA-N 0.000 claims 1
- NFWWZVHIWDPWEY-UHFFFAOYSA-N 7-chloro-4-[2-(cyclopenten-1-yl)ethylamino]-2,2,9-trimethyl-3,4-dihydropyrano[2,3-g]quinolin-3-ol Chemical compound OC1C(C)(C)OC=2C=C3C(C)=CC(Cl)=NC3=CC=2C1NCCC1=CCCC1 NFWWZVHIWDPWEY-UHFFFAOYSA-N 0.000 claims 1
- KOCXCSREADKFMD-UHFFFAOYSA-N 8-hydroxy-7,7-dimethyl-9-(2-phenylethylamino)-8,9-dihydro-4h-pyrano[2,3-g][1,4]benzoxazin-3-one Chemical compound OC1C(C)(C)OC2=CC=3NC(=O)COC=3C=C2C1NCCC1=CC=CC=C1 KOCXCSREADKFMD-UHFFFAOYSA-N 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 125000004093 cyano group Chemical group *C#N 0.000 claims 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims 1
- 125000001072 heteroaryl group Chemical group 0.000 claims 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- IQQDNMHUOLMLNJ-UHFFFAOYSA-N quinolin-3-ol Chemical compound C1=CC=CC2=CC(O)=CN=C21 IQQDNMHUOLMLNJ-UHFFFAOYSA-N 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 125000004890 (C1-C6) alkylamino group Chemical group 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000000470 constituent Substances 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 125000004430 oxygen atom Chemical group O* 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 125000002813 thiocarbonyl group Chemical group *C(*)=S 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D515/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Pyrane Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Dental Preparations (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Derivat benzopirana formule (I) ili (II), ili njegove farmaceutski prihvatljive solinaznačen time, da- R1 i R2 su metilne skupine, - R3 je hidroksi skupina, - R4 je vodikov atom, - R5 je vodikov atom. - (CH2)m-V-(CH2)n - polovica je -CH2-CH2-,- R6 je C6-14 arilna skupina koja može biti proizvoljno supstituirana sa 1 do 3 R10; C2-9 heteroarilna skupina koja može biti proizvoljno supstituirana sa 1 do 3 R10; C2-4 alkilna skupina; C3-8 cikloalkilna skupina, C3-8 cikloalkenilna skupina koja može biti proizvoljno supstituirana s atomom halogena, karboksi skupinom ili hidroksi skupinom; gdje- R10 je atom halogena. hidroksi skupina ili amino skupina; i gdje struktura prstena A je- R11 i R12 su neovisno jedan od drugoga vodikov atom ili C1-6 alkilna skupina: - R13, R14 i R15 su neovisno jedan od drugoga vodikov atom, atom halogena, cijano skupina ili C1-6 alkilna skupina koja može biti supstituirana s hidroksi skupinom ili karboksi skupinom; - X je O, S, SO ili SO2.Patent sadrži još 18 patentnih zahtjeva.
Claims (19)
1. Derivat benzopirana formule (I) ili (II), ili njegove farmaceutski prihvatljive soli
[image]
naznačen time, da
- R1 i R2 su metilne skupine,
- R3 je hidroksi skupina,
- R4 je vodikov atom,
- R5 je vodikov atom.
- (CH2)m-V-(CH2)n - polovica je -CH2-CH2-,
- R6 je C6-14 arilna skupina koja može biti proizvoljno supstituirana sa 1 do 3 R10; C2-9 heteroarilna skupina koja može biti proizvoljno supstituirana sa 1 do 3 R10; C2-4 alkilna skupina; C3-8 cikloalkilna skupina, C3-8 cikloalkenilna skupina koja može biti proizvoljno supstituirana s atomom halogena, karboksi skupinom ili hidroksi skupinom;
gdje
- R10 je atom halogena. hidroksi skupina ili amino skupina;
i gdje struktura prstena A je
[image]
- R11 i R12 su neovisno jedan od drugoga vodikov atom ili C1-6 alkilna skupina:
- R13, R14 i R15 su neovisno jedan od drugoga vodikov atom, atom halogena, cijano skupina ili C1-6 alkilna skupina koja može biti supstituirana s hidroksi skupinom ili karboksi skupinom;
- X je O, S, SO ili SO2.
2. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da R6 je C6-14 arilna skupina koja može biti proizvoljno supstituirana s 1 do 3 atoma halogena ili amino skupinom.
3. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da R6 je 2-piridilna skupina, 3-piridilna skupina ili 4-piridilna skupina.
4. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da R6 je n-propilna skupina, i-propilna skupina, c-heksilna skupina, 1-c-pentenilna skupina, 2-c-pentenilna skupina, 3-c-pentenilna skupina, 1-c-heksenilna skupina, 2-c-heksenilna skupina ili 3-c-heksenilna skupina.
5. Derivat benzopirana prema bilo kojem od zahtjeva 1 do 4, ili njegove farmaceutski prihvatljive soli, naznačen time, da derivat benzopirana je predstavljen formulom (I).
6. Derivat bcnzopirana prema bilo kojem od zahtjeva 1 do 5, ili njegove farmaceutski prihvatljive soli, naznačen time, da
- R6 je C6-14 arilna skupina koja može proizvoljno biti supstituirana s 1 do 3 atoma halogena ili amino skupinom;
- struktura prstena A je
[image]
gdje
- R11 je vodikov atom;
- R13 je vodik atom, atom halogena, C1-6 alkilna skupina koja može biti supstituirana hidroksi skupinom;
- R14 je vodikov atom; i
- R1:v je vodikov atom, atom halogena, C1-6 alkilna skupina koja može biti supstituirana hidroksi skupinom.
7. Derivat benzopirana prema bilo kojem od zahtjeva 1 do 5, ili njegove farmaceutski prihvatljive soli, naznačen time, da
- R6 je C6-14 arilna skupina koja može proizvoljno biti supstituirana s 1 do 3 atoma halogena ili amino skupinom;
- struktura prstena A je
[image]
gdje
- R11, R12, R13 i R14 su vodikov atom.
8. Derivat benzopirana prema bilo kojem od zahtjeva 1 do 5, ili njegove farmaceutski prihvatljive soli, naznačen time, da
- R6 je C6-14 arilna skupina koja može proizvoljno biti supstituirana s I do 3 atoma halogena ili amino skupinom;
- struktura prstena A je
[image]
gdje
- R11 je vodikov atom ili C1-6 alkilna skupina;
- R13 i R14 su vodikov atom; i
- X je O.
9. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je
2,2,7,9-tetrametil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
2,2,7-trimetil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
3-hidroksi-2,2,9-trimetil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinolin-7-karbonitril,
3,3-dimetil-1-[(2-feniletil)amino]-2,3-dihidro-1H-pirano[3,2-f]kinolin-2-ol,
7-hidroksimetil-2,2,9-trimetil-4-[(2-feniletil)amino]-3,4-dihidra-2H-pirano[2,3-g]kinolin-3-ol,
7-kloro-2,2,9-trimetil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
7-kloro-4-{[2-(4-fluorofenil)etil]amino}-2,2,9-trimetil-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
7-kloro-4-{[2-(4-klorofenil)etil]amino}-2,2,9-trimetil-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
4-{[2-(4-aminofenil)etil]amino}-7-kloro-2,2,9-trimetil-3,4-dihidro-2H-pirano[23-g]kinolin-3-ol,
7-kloro-2,2,9-trimetil-4-{[2-(3-piridil)etil]amino}-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
7-kloro-4-[(2-ciklopenti]etil)amino]-2,2,9-trimetil-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
7-kloro-4-{[2-(1-ciklopentenil)etil]amino}-2,2,9-trimetil-3,4-dihidro-2H-pirano[2.3-g]kinolin-3-ol,
7-kloro-2,2,9-trimetil-4-pentilamino-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
7-kloro-4-[(2-ciktaheksiletil)amino]-2,2,9-trimetil-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol,
2,2-dimetil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinoksalin-3-ol,
4-{[2-(2-fluorofenil)etil]amino}-2,2-dimetil-3,4-dihidro-2H-pirano[2,3-g]kinoksalin-3-ol,
4-{[2-(4-fluorofenil)etil]amino}-2,2-dimetil-3,4-dihidro-2H-pirano[2,3-g]kinoksalin-3-ol,
2,2-dimetil-4-(pentilamino)-3,4-dihidro-2H-pirano[2,3-g]kinoksalin-8-ol,
4-[(2-cikloheksiletil)amino]-2,2-dimetil-3,4-dihidro-2H-pirano[2,3-g]kinoksalin-3-ol,
7-hidroksi-6,6-dimetil-8-[(2-feniletil)amino]-4,6,7,8-tetrahidro-1,5-dioksa-4-aza-antracen-3-on,
7-hidroksi-4,6,6-dimetil-8-[(2-feniletil)amino]-4,6,7,8-tetrahidro-1,5-dioksa-4-aza-antracen-3-on,
7-hidroksi-6,6-dimetil-8-[(2-feniletil)amino]-1,6,7,8-tetrahidro-4,5-dioksa-1-aza-antracen-2-on,
2,2-dimetil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol.
10. Derivat bcnzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je 2,2,7-trimetil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol.
11. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je 7-hidroksimetil-2,2,9-trimetil-4-[(2-feniletil)amino]-3.4-dihidro-2H-pirano[2,3-g]kinolin-3-ol.
12. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je 7-kloro-2,2,9-trimetil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol.
13. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je 7-kloro-2,2,9-trimetil-4-{[2-(3-piridil)etil]amino}-3,4-dihidro-2H-pirano[2,3-g]kinolin-3-ol.
14. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je 7-kloro-4-[(2-cikloheksiletil)amino]-2,2,9-trimetil-3,4-dihidro-2H-pirano[2.3-g]kinolin-3-ol.
15. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je 2,2-dimetil-4-[(2-feniletil)amino]-3,4-dihidro-2H-pirano[2,3-g]kinoksalin-3-ol.
16. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je 4-{[2-(2-fluorofenil)etil]amino}-2,2-dimetil-3,4-dihidro-2H-pirano[2.3-g]kinoksalin-3-ol.
17. Derivat benzopirana prema zahtjevu 1, ili njegove farmaceutski prihvatljive soli, naznačen time, da je 7-hidroksi-6,6-dimetil-8-[(2-feniletil)amino]-1,6,7,8-tetrahidro-4,5-dioksa-1-aza-antracen-2-on.
18. Farmaceutski pripravak, naznačen time, da kao aktivni sastojak sadrži derivat benzopirana ili njegove farmaceutski prihvatljive soli, kako je određeno u bilo kojem zahtjevu 1 do 17.
19. Farmaceutski pripravak, prema zahtjevu 18, naznačen time, da se upotrebljava u postupku liječenja aritmije.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2004084605 | 2004-03-23 | ||
| PCT/JP2005/006004 WO2005090357A1 (en) | 2004-03-23 | 2005-03-23 | Tricyclic benzopyran compound as anti-arrhythmic agents |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20110005T1 true HRP20110005T1 (hr) | 2011-02-28 |
Family
ID=34962589
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HR20110005T HRP20110005T1 (hr) | 2004-03-23 | 2011-01-05 | Spoj tricikličkog benzopirana kao anti-aritmijskog sredstva |
Country Status (31)
| Country | Link |
|---|---|
| US (2) | US7652008B2 (hr) |
| EP (1) | EP1732929B1 (hr) |
| JP (1) | JP4840594B2 (hr) |
| KR (2) | KR101085979B1 (hr) |
| CN (3) | CN1934116B (hr) |
| AT (1) | ATE485299T1 (hr) |
| AU (2) | AU2005223612B2 (hr) |
| BR (1) | BRPI0508768A (hr) |
| CA (1) | CA2558139C (hr) |
| CY (1) | CY1111250T1 (hr) |
| CZ (1) | CZ2006598A3 (hr) |
| DE (1) | DE602005024245D1 (hr) |
| DK (1) | DK1732929T3 (hr) |
| EG (1) | EG27163A (hr) |
| ES (1) | ES2353021T3 (hr) |
| HK (1) | HK1099299A1 (hr) |
| HR (1) | HRP20110005T1 (hr) |
| IL (1) | IL177950A (hr) |
| MX (1) | MXPA06010880A (hr) |
| NO (1) | NO339495B1 (hr) |
| NZ (2) | NZ549570A (hr) |
| PL (1) | PL1732929T3 (hr) |
| PT (1) | PT1732929E (hr) |
| RS (1) | RS51742B (hr) |
| RU (1) | RU2380370C2 (hr) |
| SI (1) | SI1732929T1 (hr) |
| SK (1) | SK287994B6 (hr) |
| TW (1) | TWI352704B (hr) |
| UA (1) | UA91189C2 (hr) |
| WO (1) | WO2005090357A1 (hr) |
| ZA (1) | ZA200607388B (hr) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS51742B (en) * | 2004-03-23 | 2011-10-31 | Nissan Chemical Industries Ltd. | TRICYCLIC BENZOPIRAN UNITS AS ANTIARITHMIC AGENTS |
| US8394974B2 (en) | 2006-03-10 | 2013-03-12 | Nissan Chemical Industries, Ltd. | Process for producing optically active chromene oxide compound |
| TW201022223A (en) * | 2008-08-14 | 2010-06-16 | Nissan Chemical Ind Ltd | Di-substituted benzopyrane compound |
| TWI480281B (zh) * | 2009-04-30 | 2015-04-11 | Nissan Chemical Ind Ltd | 三環性苯并哌喃化合物的新穎結晶形態及其製造方法 |
| NZ597107A (en) | 2009-06-25 | 2013-12-20 | Alkermes Pharma Ireland Ltd | Heterocyclic compounds for the treatment of neurological and psychological disorders |
| WO2014050613A1 (ja) * | 2012-09-27 | 2014-04-03 | 日産化学工業株式会社 | 含窒素複素環ｎ－オキシド化合物の製造方法 |
| CN104507949B (zh) * | 2012-09-27 | 2017-07-28 | 日产化学工业株式会社 | 高纯度的含氮杂环化合物的制造方法 |
| EP3026047A4 (en) * | 2013-07-25 | 2017-05-17 | Nissan Chemical Industries, Ltd. | Method for producing heterocyclic compound |
| EP3567044A4 (en) * | 2017-01-06 | 2020-06-10 | Korea University Research and Business Foundation, Sejong Campus | INNOVATIVE CHINOLINONE DERIVATIVE AND PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF ALLERGIC DISEASES LIKE ASTHMA OR ATOPIA THEREFORE AS AN ACTIVE SUBSTANCE |
| CN112423754A (zh) | 2018-03-05 | 2021-02-26 | 奥克梅斯制药爱尔兰有限公司 | 阿立哌唑的给药策略 |
| CN108727261B (zh) * | 2018-06-21 | 2021-09-24 | 济南大学 | 一种硝基取代喹那啶的制备方法 |
| JP7468869B2 (ja) | 2018-12-28 | 2024-04-16 | 国立大学法人大阪大学 | 遺伝性徐脈性不整脈治療薬 |
| RU2754610C1 (ru) * | 2020-04-14 | 2021-09-03 | Георгий Викторович ТЕЦ | Препарат для лечения заболеваний, вызванных бактериями |
| JPWO2021261598A1 (hr) | 2020-06-26 | 2021-12-30 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZM7682A1 (en) | 1981-09-25 | 1983-05-23 | Beecham Group Plc | Active compounds |
| JPS5867683U (ja) | 1981-10-28 | 1983-05-09 | 株式会社ナムコ | 歩行ロボツト |
| JPH0699439B2 (ja) | 1988-02-03 | 1994-12-07 | 日産化学工業株式会社 | ピラノベンゾオキサジアゾール誘導体 |
| JP2658198B2 (ja) | 1988-06-23 | 1997-09-30 | 日産化学工業株式会社 | ピラノベンゾトリアゾール誘導体 |
| US5097037A (en) | 1989-07-17 | 1992-03-17 | Nissan Chemical Industries, Ltd. | Process for the optical resolution of pyranobenzoxadiazole compounds |
| JP2876712B2 (ja) * | 1989-07-17 | 1999-03-31 | 日産化学工業株式会社 | 光学活性ピラノベンゾオキサジアゾール誘導体 |
| US5164509A (en) * | 1990-11-26 | 1992-11-17 | E. R. Squibb & Sons, Inc. | Benzodiazolo analogs |
| KR960700713A (ko) | 1993-04-02 | 1996-02-24 | 도쿠시마 슈이치 | 심부전증 치료약(medicines for cardiac insufficiency) |
| JPH07300414A (ja) * | 1993-04-02 | 1995-11-14 | Nissan Chem Ind Ltd | 心不全治療薬 |
| JP2734457B2 (ja) | 1994-02-23 | 1998-03-30 | 日産化学工業株式会社 | 不斉エポキシ化反応 |
| DE69518322T2 (de) | 1994-06-10 | 2001-02-15 | Smithkline Beecham Plc | C-4 amid substituierte verbindungen und deren verwendung als therapeutische mittel |
| EP0807629B1 (de) * | 1996-05-15 | 2004-03-03 | Aventis Pharma Deutschland GmbH | Sulfonamid-substituierte Chromane, Verfahren zu ihrer Herstellung, ihre Verwendung als Medikament oder Diagnostikum sowie sie enthaltendes Medikament |
| US6486178B1 (en) | 1998-06-03 | 2002-11-26 | Nissan Chemical Industries, Ltd. | Indane derivatives |
| AU5444499A (en) | 1998-09-01 | 2000-03-21 | Nissan Chemical Industries Ltd. | Benzoxazine derivatives |
| WO2000058300A1 (fr) | 1999-03-25 | 2000-10-05 | Nissan Chemical Industries, Ltd. | Derives du chroman |
| HUP0202690A3 (en) | 1999-09-17 | 2005-02-28 | Nissan Chemical Ind Ltd | Benzopyran derivative having antiarrhytmic activity |
| US6555574B1 (en) | 1999-09-24 | 2003-04-29 | Nissan Chemical Industries, Ltd. | 4-oxybenzopyran derivative |
| EP1218367A1 (en) | 1999-10-05 | 2002-07-03 | Nissan Chemical Industries, Ltd. | 4-oxybenzopyran derivative |
| TW589305B (en) | 2001-02-14 | 2004-06-01 | Nissan Chemical Ind Ltd | 4-aminobenzopyran derivatives |
| CZ20033469A3 (cs) | 2001-06-25 | 2004-04-14 | Nissan Chemical Industries, Ltd. | Substituované benzopyranové deriváty proti arytmiím |
| WO2003014113A1 (en) | 2001-08-06 | 2003-02-20 | Glenmark Pharmaceuticals Limited | Novel benzopyran compounds and process for their preparation and use |
| RS51742B (en) * | 2004-03-23 | 2011-10-31 | Nissan Chemical Industries Ltd. | TRICYCLIC BENZOPIRAN UNITS AS ANTIARITHMIC AGENTS |
-
2005
- 2005-03-23 RS RS20110028A patent/RS51742B/en unknown
- 2005-03-23 ZA ZA200607388A patent/ZA200607388B/en unknown
- 2005-03-23 CA CA2558139A patent/CA2558139C/en not_active Expired - Fee Related
- 2005-03-23 SI SI200531171T patent/SI1732929T1/sl unknown
- 2005-03-23 CN CN2005800090295A patent/CN1934116B/zh active Active
- 2005-03-23 CN CN2008101707921A patent/CN101429200B/zh not_active Expired - Fee Related
- 2005-03-23 KR KR1020107027058A patent/KR101085979B1/ko active IP Right Grant
- 2005-03-23 US US10/590,975 patent/US7652008B2/en active Active
- 2005-03-23 AT AT05727581T patent/ATE485299T1/de active
- 2005-03-23 RU RU2006137284/04A patent/RU2380370C2/ru not_active IP Right Cessation
- 2005-03-23 DE DE602005024245T patent/DE602005024245D1/de active Active
- 2005-03-23 BR BRPI0508768-6A patent/BRPI0508768A/pt not_active Application Discontinuation
- 2005-03-23 UA UAA200611101A patent/UA91189C2/ru unknown
- 2005-03-23 PL PL05727581T patent/PL1732929T3/pl unknown
- 2005-03-23 WO PCT/JP2005/006004 patent/WO2005090357A1/en active Application Filing
- 2005-03-23 PT PT05727581T patent/PT1732929E/pt unknown
- 2005-03-23 DK DK05727581.0T patent/DK1732929T3/da active
- 2005-03-23 MX MXPA06010880A patent/MXPA06010880A/es active IP Right Grant
- 2005-03-23 CZ CZ20060598A patent/CZ2006598A3/cs unknown
- 2005-03-23 CN CN2011100751168A patent/CN102190661B/zh not_active Expired - Fee Related
- 2005-03-23 AU AU2005223612A patent/AU2005223612B2/en not_active Ceased
- 2005-03-23 NZ NZ549570A patent/NZ549570A/en unknown
- 2005-03-23 EP EP05727581A patent/EP1732929B1/en active Active
- 2005-03-23 NZ NZ585606A patent/NZ585606A/en unknown
- 2005-03-23 SK SK5079-2006A patent/SK287994B6/sk not_active IP Right Cessation
- 2005-03-23 KR KR1020067021988A patent/KR101019402B1/ko active IP Right Grant
- 2005-03-23 ES ES05727581T patent/ES2353021T3/es active Active
- 2005-03-23 JP JP2006530022A patent/JP4840594B2/ja active Active
- 2005-03-23 TW TW094108962A patent/TWI352704B/zh active
-
2006
- 2006-09-02 EG EGNA2006000900 patent/EG27163A/xx active
- 2006-09-07 IL IL177950A patent/IL177950A/en not_active IP Right Cessation
- 2006-10-23 NO NO20064819A patent/NO339495B1/no not_active IP Right Cessation
-
2007
- 2007-06-15 HK HK07106502.1A patent/HK1099299A1/xx unknown
-
2009
- 2009-11-17 US US12/591,353 patent/US7964623B2/en not_active Expired - Fee Related
-
2010
- 2010-07-08 AU AU2010202900A patent/AU2010202900B2/en not_active Ceased
-
2011
- 2011-01-05 HR HR20110005T patent/HRP20110005T1/hr unknown
- 2011-01-19 CY CY20111100060T patent/CY1111250T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20110005T1 (hr) | Spoj tricikličkog benzopirana kao anti-aritmijskog sredstva | |
| ES2298439T3 (es) | Heterociclos biciclicos que contienen nitrogeno para uso como agentes antibacterianos. | |
| DE60307860T2 (de) | Aminocyclohexenchinoline und ihre azaisosterischen Analoga mit antibakterieller Wirkung | |
| EA200601192A1 (ru) | ЗАМЕЩЁННЫЕ ПРОИЗВОДНЫЕ 8'-ПИРИ(МИ)ДИНИЛДИГИДРОСПИРО[ЦИКЛОАЛКИЛАМИН]ПИРИМИДО[1,2-a]ПИРИМИДИН-6-ОНА | |
| EA200600196A1 (ru) | Производные замещенного 2-пиримидинил-6,7,8,9-тетрагидропиримидо[1,2-a]пиримидин-4-она и 7-пиримидинил-2,3-дигидроимидазо[1,2-a]пиримидин-5(1н) она для нейродегенеративных нарушений | |
| IL157819A0 (en) | Triazaspiro [5.5] undecane dericatives and drugs containing the same as the active ingredient | |
| AR064608A1 (es) | Derivados de pirazolo-quinazolina sustituidos, composiciones farmaceuticas que los contienen. proceso para su preparacion y uso de los mismos como agentes anticancer. | |
| HUP0401481A2 (hu) | Kinolinszármazékok, mint neuropeptid Y antagonisták, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények | |
| WO2004082577A3 (en) | 8-SUBSTITUTED-6, 7, 8, 9-TETRAHYDROPYRIMIDO[1,2-a] PYRIMIDIN-4-ONE DERIVATIVES | |
| ES2083773T3 (es) | Derivados de 1,3-dihidro-2h-imidazo(4,5-b)quinolin-2-ona como inhibidores de fosfodiesterasa. | |
| CA2344290A1 (en) | Quinazoline derivatives | |
| HRP20140010T1 (hr) | Derivati 5-amino-2-(1-hidroksi-etil)-tetrahidropirana | |
| TW200510418A (en) | Substituted 8'-pyridinyl-dihydrospiro-[cycloalkyl]-pyrimido [1, 2-a] pyrimidin-6-one and 8'-pyrimidinyl-dihydrospiro-[cycloalkyl]-pyrimido [1, 2-a] pyrimidin-6-one derivatives | |
| WO2003027116A3 (en) | Substituted 2-pyridinyl-6,7,8,9-tetrahydropyrimido[1,2-a]pyrimidin-4-one and 7-pyridinyl-2,3-dihydroimidazo[1,2-a]pyrimidin-5(1h)one derivatives | |
| AR038835A1 (es) | Derivados de nicotinamida y una sal de tiotropio en combinacion para tratar enfermedades, el compuesto activo, una composicion farmaceutica que incluye la combinacion y uso de esta para la fabricacion de un farmaco | |
| BRPI0408605A (pt) | derivados de 8-perfluoralquil-6,7,8,9-tetrahidropirimido[1,2-a]piri midin-4-ona substituìdos | |
| MX2009004884A (es) | Derivados 8-piperidinil-2-piridinil-pirimido [1,2-a] pirimidin-6-ona y 8-piperidinil-2-pirimidinil-pirimido [1,2-a] pirimidin-6-ona sustuidos. | |
| MA27064A1 (fr) | 6,7-dihydro-5h-pyrazolo[1,2-a]pyrazol-1-ones spirocycliques regulant les cytokines inflammatoires. | |
| ATE261445T1 (de) | Neue 1,8-naphtyridin-2(1h)-on-derivate | |
| DE68918755D1 (de) | 5-Substituierte Imidazo[4,5-c]pyridine. | |
| RU2002121245A (ru) | Средство против кислотоустойчивых бактерий, содержащее пиридонкарбоновые кислоты в качестве активного компонента | |
| DE69217511D1 (de) | Pyridazindionderivate, ihre Herstellung und Verwendung als Arzneimittel | |
| AU2004240167B2 (en) | Anti acid-fast bacterial agent containing pyridonecarboxylic acids as active ingredient | |
| CA2203664A1 (en) | Substituted tetracyclic oxazepine and thiazepine derivatives with 5-ht2 receptor affinity | |
| WO2002102808A3 (en) | (PYRIDO/THIENO)-[f]-OXAZEPIN-5-ONE DERIVATIVES AS POSITIVE MODULATORS OF THE AMPA RECEPTOR |